NCT04382326

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,997 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 42 Days – 98 Days
• Healthy volunteers: Accepted

Summary

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

Conditions

• Pneumococcal Disease

Interventions

Type	Name	Description
BIOLOGICAL	20-valent pneumococcal conjugate vaccine	20-valent pneumococcal conjugate vaccine
BIOLOGICAL	13-valent pneumococcal conjugate vaccine	13-valent pneumococcal conjugate vaccine

Timeline

• Start date: 2020-05-20
• Primary completion: 2022-09-02
• Completion: 2022-09-02
• First posted: 2020-05-11
• Last updated: 2023-12-06
• Results posted: 2023-12-06

Locations

110 sites across 2 countries: United States, Puerto Rico

Regulatory

• FDA-regulated drug study